DFDA

Adalimumab

Treatment for Pyoderma

Typical Dosage: 80 mg SC initial, then 40 mg SC every other week

Effectiveness
85%
Safety Score
48%
Clinical Trials
4
Participants
500

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
80 mg SC initial, then 40 mg SC every other week
Time to Effect
4-8 weeks
Treatment Duration
Long-term (induction then maintenance)
Evidence Quality
HIGH
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$45,000
Monitoring:$1,000
Side Effect Mgmt:$500
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$42,272.73/QALY
QALYs Gained
1.1
Outcome-Based Costs
Cost per Responder
$62,000
Cost per Remission
$93,000
Adalimumab Outcomes

for Pyoderma

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+75%
Remission Rate
+50%
Common Side Effects
Injection site reactions
+15%
Upper respiratory tract infection
+20%
Headache
+12%
Serious infections (e.g., TB reactivation)
+2%

Sources:

mdpi.com
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for Adalimumab in Pyoderma

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

NCT03311464COMPLETEDPHASE3
View Study
22 participants
INTERVENTIONAL
Nagoya, Japan +19 more
Started: Oct 27, 2017

A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)

NCT04750213COMPLETED
View Study
60 participants
OBSERVATIONAL
Nagoya, Japan +45 more
Started: Feb 12, 2021